{"id":6151,"date":"2019-10-15T16:04:24","date_gmt":"2019-10-15T10:34:24","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=6151"},"modified":"2021-07-24T12:57:35","modified_gmt":"2021-07-24T07:27:35","slug":"recent-pharma-happenings-for-imaginab-pfizer-takeda","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-imaginab-pfizer-takeda","title":{"rendered":"ImaginAb joins hands with AstraZeneca, Pfizer, Takeda"},"content":{"rendered":"\n

ImaginAb has collaborated with\nAstraZeneca, Pfizer and Takeda to develop technology to facilitate tumour\nimaging and monitoring inside the cells. <\/strong><\/h4>\n\n\n\n

ImaginAb is an emerging imaging\ncompany focused on immune-oncology. The technology also helps in targeting and\nvisualizing CD8+ T cells, which are activated by the immunotherapy and induce\ncell death. <\/p>\n\n\n\n

Under the terms of the agreement, the collaborators will advance the current ImaginAb-sponsored clinical trials that aim to study the utility and value of CD8 ImmunoPet in the immune-oncology pipeline. <\/p>\n\n\n\n

In return, collaborators will\ngain access to data of clinical and imaging data that will help them analyse the\npost-clinical results. <\/p>\n\n\n\n

ImaginAb\u2019s is developing Minibodies\nthat preserve their whole length while being inert in the body. Advancing the\npipeline of minibodies to target cancer, including CD8 ImmunoPET targeting CD8\nT cells, the company believes its products can add quality to the lives of cancer\npatients. <\/p>\n\n\n\n

The company is already working with major pharma players such as Merck & Co., Boehringer Ingelheim, Nektar and Roche, some of the major players in cancer immunotherapy, backed by venture capital firms including The Parker Institute for Cancer Immunotherapy, Nextech Invest, Adage Capital, The Cycad Group, Merck (MSD) Pharma, Novartis Bioventures and Jim Pallotta of the Raptor Group.<\/p>\n\n\n\n

Aytu BioScience enters into an\nagreement with Cerecor to gain access to a portfolio of prescription products\nfor USD 17 Million. <\/strong><\/h4>\n\n\n\n

The transaction will be done in two modes in cash worth USD 4.5 Million and USD 12.5 Million worth stocks.  This agreement will add approximately USD 44 Million to the revenue of Aytu BioSciences. The revenue is also added by the previous acquisition of Innovus Pharmaceuticals.<\/p>\n\n\n\n

The acquired assets consist of\nsix established primary pediatric care products including: AcipHex Sprinkle,\nCefaclor for Oral Suspension, Karbinal ER, Flexichamber, Poly-Vi-Flor and\nTri-Vi-Flor.<\/p>\n\n\n\n

Aytu BioSciences is a company aiming to commercialize novel products to address patients\u2019 needs, committed to treating problems like hypogonadism<\/a>, severe cough and respiratory symptoms, insomnia<\/a>, and male infertility.<\/p>\n\n\n\n

Akorn, a leading\npharmaceutical firm, has recently received a new Abbreviated New Drug\nApplication (ANDA) approval the FDA for its betamethasone dipropionate lotion. <\/strong><\/h4>\n\n\n\n

According to IQVIA, U.S. sales of\nbetamethasone dipropionate lotion (augmented), 0.05% were approximately $10\nmillion for the twelve months ended August 2019.<\/p>\n\n\n\n

Betamethasone dipropionate lotion, a strong corticosteroid, is used to treat several types of skin conditions like eczema<\/a>, dermatitis<\/a>, allergies<\/a>, rash. Indicated to provide relief from inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older, it is manufactured at Akorn\u2019s Amityville, New York manufacturing facility. <\/p>\n","protected":false},"excerpt":{"rendered":"

ImaginAb has collaborated with AstraZeneca, Pfizer and Takeda to develop technology to facilitate tumour imaging and monitoring inside the cells. ImaginAb is an emerging imaging company focused on immune-oncology. The technology also helps in targeting and visualizing CD8+ T cells, which are activated by the immunotherapy and induce cell death. Under the terms of the […]<\/p>\n","protected":false},"author":1,"featured_media":6152,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[96,1271,17797,460,639,5789,554],"industry":[17225],"therapeutic_areas":[17278],"class_list":["post-6151","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-astrazeneca","tag-delveinsight-pharma-news","tag-imaginab","tag-pfizer","tag-pharma-news","tag-recent-pharma-news","tag-takeda","industry-pharmaceutical","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"\nImaginAb's collaboration; Aytu's agreement; Approval for Betamethasone<\/title>\n<meta name=\"description\" content=\"ImaginAb has collaborated with AstraZeneca, Pfizer and Takeda to develop technology to facilitate tumour imaging and monitoring inside the cells.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-imaginab-pfizer-takeda\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImaginAb's collaboration; Aytu's agreement; Approval for Betamethasone\" \/>\n<meta property=\"og:description\" content=\"ImaginAb has collaborated with AstraZeneca, Pfizer and Takeda to develop technology to facilitate tumour imaging and monitoring inside the cells.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-imaginab-pfizer-takeda\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-10-15T10:34:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09024012\/News_15.10.2019.png\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ImaginAb's collaboration; Aytu's agreement; Approval for Betamethasone","description":"ImaginAb has collaborated with AstraZeneca, Pfizer and Takeda to develop technology to facilitate tumour imaging and monitoring inside the cells.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-imaginab-pfizer-takeda","og_locale":"en_US","og_type":"article","og_title":"ImaginAb's collaboration; Aytu's agreement; Approval for Betamethasone","og_description":"ImaginAb has collaborated with AstraZeneca, Pfizer and Takeda to develop technology to facilitate tumour imaging and monitoring inside the cells.","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-imaginab-pfizer-takeda","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-10-15T10:34:24+00:00","article_modified_time":"2021-07-24T07:27:35+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09024012\/News_15.10.2019.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-imaginab-pfizer-takeda","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-imaginab-pfizer-takeda","name":"ImaginAb's collaboration; Aytu's agreement; Approval for Betamethasone","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-imaginab-pfizer-takeda#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-imaginab-pfizer-takeda#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09024012\/News_15.10.2019.png","datePublished":"2019-10-15T10:34:24+00:00","dateModified":"2021-07-24T07:27:35+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"ImaginAb has collaborated with AstraZeneca, Pfizer and Takeda to develop technology to facilitate tumour imaging and monitoring inside the cells.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-imaginab-pfizer-takeda"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-imaginab-pfizer-takeda#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09024012\/News_15.10.2019.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09024012\/News_15.10.2019.png","width":772,"height":482,"caption":"Pharma News"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/10\/09024012\/News_15.10.2019-300x187.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AstraZeneca<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">delveinsight pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">ImaginAb<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pfizer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Takeda<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AstraZeneca<\/span>","<span class=\"advgb-post-tax-term\">delveinsight pharma news<\/span>","<span class=\"advgb-post-tax-term\">ImaginAb<\/span>","<span class=\"advgb-post-tax-term\">Pfizer<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Takeda<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Oct 15, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Oct 15, 2019 4:04 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"Pharma News","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6151","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=6151"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/6151\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/6152"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=6151"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=6151"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=6151"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=6151"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=6151"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}